Menu

An expert resource for medical professionals
Provided FREE as a service to women’s health

The Alliance for
Global Women’s Medicine
A worldwide fellowship of health professionals working together to
promote, advocate for and enhance the Welfare of Women everywhere

An Educational Platform for FIGO

The Global Library of Women’s Medicine
Clinical guidance and resources

A vast range of expert online resources. A FREE and entirely CHARITABLE site to support women’s healthcare professionals

The Global Academy of Women’s Medicine
Teaching, research and Diplomates Association

This chapter should be cited as follows:
Ng WL, Chung E, et al, Glob. libr. women's med.,
ISSN: 1756-2228; DOI 10.3843/GLOWM.418593

The Continuous Textbook of Women’s Medicine SeriesGynecology Module

Volume 4

Benign gynecology

Volume Editor: Professor Shilpa Nambiar, Prince Court Medical Centre, Kuala Lumpur, Malaysia

Chapter

Magnetic Resonance-Guided Focused Ultrasound for Uterine Fibroids

First published: May 2024

Study Assessment Option

By completing 4 multiple-choice questions (randomly selected) after studying this chapter readers can qualify for Continuing Professional Development awards from FIGO plus a Study Completion Certificate from GLOWM
See end of chapter for details

EPIDEMIOLOGY OF UTERINE FIBROIDS

Uterine fibroids in general

Uterine fibroids or leiomyomas are common benign tumors of the uterus in women of reproductive age. They are the most common benign gynecological tumors in women of childbearing age, with prevalence of 20–25% and up to 80% of women by 50 years of age.1,2 It often causes clinical symptoms such as menorrhagia or dysmenorrhea, pelvic pain, increased abdominal pressure and fertility problems, depending on their size and location. The presence of uterine fibroid in pregnancy has been associated with an increased rate of spontaneous abortions. The indication for cesarean delivery in these cases is most commonly due to malpresentation but may also be due to the presence of placenta previa. Symptoms of adenomyosis are very similar to those of fibroid and both can occur in the same patient. A junctional zone width of more than 12 mm is defined as adenomyosis. It is not uncommon to have patients referred for screening as fibroids but subsequently found to have adenomyosis (35–55%) after magnetic resonance imaging (MRI).3

Fibroid types

There are three types of uterine fibroids depending on their location; intramural (IM), submucosal (SM), and subserosal (SS) (Figure 1). Intramural fibroids lie within the wall of the uterus, separated from myometrium by a layer of connective tissue, submucosal fibroids usually protrude into the endometrial cavity and distort the endometrium, and subserosal fibroids are on the surface of the uterus and usually are growing outward. It is suggested that high-intensity focused ultrasound (HIFU) might be suitable treatment for pedunculated subserosal fibroids although the ablation of these fibroids might lead to stalk detachment of the fibroid from the uterus and expulsion into the abdominal cavity.4 The pathway of submucosal fibroids might cause severe endometrial impairment so it is suggested to treat up in the endometrial surface of women who do not wish to preserve their fertility.

1

Type of fibroids and their locations.

Financial impact

The surgical and non-surgical therapies of uterine fibroids including the indirect costs contribute tremendously to the societal and economic burden. The greatest impact however is the cost of time lost from work rather than the direct treatment itself. The direct costs of uterine fibroids include surgery, hospital admission, outpatient visits, and medication. Based on an analysis done by Cardazo et al. on a 2010 population estimate, the annual direct cost of uterine fibroids ranged from $4.1–9.4 billion.5 Further break down of these figures showed that surgical treatment is significantly higher compared to non-surgical therapy (Table 1). Being absent from work and short-term disability contributed to annual lost work time cost. However, the total estimated annual lost work time cost is higher than the direct cost of uterine fibroids with a range of $1.55–17.2 billion.5 The highest group of patients are those that managed their fibroid non-surgically with an expense of $549 million–$9.4 billion.5 The lowest annual lost work time cost are those women who underwent endometrial ablation with a range of $4–248 million (Table 2).

1

Estimated direct cost of uterine fibroid tumors.5

Range of women undergoing each intervention (%)


Cost estimates ($)


Estimate of total cost ($)

Variable

Low

High

Low

High

Low

High

Medical management: medications, inpatient admission, outpatient visits




55635

86656


3,271,956,332

5,096,441,060

Surgical management

  • Hysterectomy
  • Myomectomy
  • Uterine artery
  • Endometrial ablation


21.005

 1.0024

 0.2024

 0.165


52.908

 5.9325

 1.7725

 2.4325


62877

68057

68057

49438


11,5388

14,8507

12,8638

  49438


776,532,518

 40,027,010

  8,002,680

  4,651,363


3,589,921,782

  517,938,300

  133,916,693

   70,645,356

Total direct cost





4,101,169,903

9,408,863,191

Note: total number of women who sought treatment for fibroid tumors was calculated in the following manner: the number of women aged 25–54 years (63,930,821) × baseline prevalence (0.92%) = 588,164. All costs are reported in 2010 dollars (US).

2

Estimated annual lost work time cost (absenteeism and short-term disability).5

Range of women undergoing each intervention (%)


Range of cost estimates6,8 ($)


Estimate of total cost ($)

Variable

Low

High

Low

High

Low

High

Hysterectomy

21.005

52.908


4449

30,075


  549,513,786

 9,357,475,350

Myomectomy

 1.0024

 5.9325

4449

25,164

   26,169,018

   877,669,992

Uterine artery embolization

 0.2024

 1.7725

4449

18,836

    5,232,204

   196,101,596

Endometrial ablation

 0.165

 2.4325

4449

17,385

    4,186,509

   248,466,420

No surgical treatment

36.97  

77.64  

4449

14,282

  967,408,356

 6,521,889,582

Total cost of lost work time





1,552,509,693

17,201,602,940

Note: total women who sought treatment for fibroid tumors was calculated in the following manner: the number of women aged 25–54 years (63,930,821) × baseline prevalence (0.92%) = 588,164. All costs are reported in 2010 dollars (US).

Treatment options

Treatment options include surgical and non-surgical treatment. Surgical treatment would be more definitive with total removal of the lesion. In a hysterectomy, it eliminates the symptoms and recurrence, however it would not be suitable for women in the reproductive age group who plan to conceive. Myomectomy, MRgFUS, uterine artery embolization and gonadotropin-releasing hormone agonists are alternatives for women who wish for uterine conservation. However, MRgFUS is the only non-invasive approach. The table below lists the comparison of recommended therapies for uterine fibroid compiled by American Family Physician 2017 (Table 3).6

3

Comparison of recommended therapies for uterine fibroids

Treatment

Description

Advantages

Medical therapies



Gonadotropin-releasing hormone agonists

Preoperative treatment to decrease size of tumors before surgery or in women approaching menopause

Decrease blood loss, operative time, and recovery time

Levonorgestrel-releasing intrauterine system (Mirena)

Treats abnormal uterine bleeding likely by stabilization of endometrium

Most effective medical treatment for reducing blood loss; decreases fibroid volume

Non-steroidal anti-inflammatory drugs

Anti-inflammatories and prostaglandin inhibitors

Reduce pain and blood loss from fibroids

Oral contraceptives

Treat abnormal uterine bleeding, likely by stabilization of endometrium

Reduce blood loss from fibroids; ease of conversion to alternate therapy if not successful

Selective progesterone receptor modulators

Preoperative treatment to decrease size of tumors before surgery or in women approaching menopause

Decrease blood loss, operative time and recovery time; not associated with hypoestrogenic adverse effects

Tranexamic acid (Cyklokapron)

Antifibrinolytic therapy

Reduces bloody loss from fibroids; ease of conversion to alternate therapy

Surgical therapies



Hysterectomy

Surgical removal of the uterus (transabdominally, transvaginally, or laparoscopically)

Definitive treatment for women who do not wish to preserve fertility; transvaginal and laparoscopic approach associated with decreased pain, blood loss and recovery time compared with transabdominal surgery

Magnetic resonance–guided focused ultrasound surgery

In situ destruction by high-intensity ultrasound waves

Non-invasive approach; shorter recovery time with modest symptom improvement

Myomectomy

Surgical or endoscopic excision of tumors

Resolution of symptoms with preservation of fertility

Uterine artery embolization

Interventional radiologic procedure to occlude uterine arteries

Minimally invasive; avoids surgery; short hospitalization

Information from De la Cruz 2017.6

MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND SURGERY (MRGFUS)

Introduction

Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is an alternative to myomectomy that is without a surgical incision or any major complication. It is a non-invasive technique that causes immediate coagulative necrosis in 1–3 s and can be performed under either magnetic resonance imaging (MRI) guidance or ultrasound guidance and in a well circumscribed area measuring a few mm in diameter.7 The biological effects of HIFU were investigated by Wood and Loomis in 1927 and the first therapeutic trial with focused ultrasound was performed by Lynn et al. in 1940s.8 The HIFU ablation of uterine fibroids is affected by internal structures such as blood supply, water content, and fiber composition and also by location, type, and size of the uterine fibroids.9 MRgFUS is capable of monitoring dangerous temperature elevations, which ensure the safety and effectiveness of the procedure. The temperature at the focal region can accurately predict the ablation effect in the treatment of uterine fibroids. The procedure also provides real-time feedback to adjust the sonification energy and power. The success of the treatment is measured post procedure by measuring the non-perfused volume (NPV) on contrast-enhanced MR imaging.

Principle

This system combines MRI and focused ultrasound to form a “closed-loop therapy and feedback system” that enables the physician to adjust treatment parameters and control the treatment, helping to maintain a high level of safety and efficacy. The system which received FDA approval in 2004 is known as ExAblate 2000 (InSightec, Haifa, Israel) is used with a 1.5 Tesla MR scanner (GE Medical Systems, Milwaukee).

  • An MRI scanner is used for 3D imaging of anatomical and thermal mapping, which permit high-resolution visualization of the patient's anatomy for planning of treatment, and quantitative information on the change in tissue temperature to monitor and control the treatment (Figure 2).
  • Therapeutic focused ultrasound (FUS) energy on a specific point is where sound waves converge and produce the highest energy to heat and ablate the tissue within the body without damaging the tissue along the beam path. Known as ‘sonication’, the focused ultrasound destroys tissues at a temperature of 60–85°C. Multiple sonications (focal delivery of energy) are required to ablate a specific tissue (Figure 3).

2

MR thermometry showing real-time temperature to monitor and control the treatment. Reproduced with permission from InSightec.24

3

Focused ultrasound energy on a specific point is where sound waves converge and produce the highest energy to heat and ablate the fibroid without damaging the tissue along the beam path. Reproduced with permission from InSightec.24

Patient selection

If the patient is clinically eligible and interested in MRgFUS, they are then referred for screening MRI scans. Screening should be performed in the prone position and the MRI protocol consists of T2 weighted images, T1 weighted images pre and post gadolinium injection in three planes. The T2 weighted imaging is to determine anatomy and pathological conditions and the T1 weighted imaging with and without contrast agent is to identify fibroid viability. Patients are deemed technically suitable for MRgFUS if their fibroids are accessible by the system and treatable within a reasonable time (Figure 4).

4

Selection of patient also depends on the position of surrounding structures i.e., bowel, nerve, surgical clips and scars. Reproduced with permission from InSightec.24

There are four factors that are important in patient selection:

  • Number of fibroids;
  • Fibroid volume;
  • Fibroid intensity;
  • Subcutaneous fat layer.

1. Number of fibroids

The guideline recommends treating patients with up to six fibroids and not more than 4 cm in size. In the case of multiple fibroids, some may be inaccessible or not treatable. In patients with symptoms of bleeding, the fibroids with a submucosal component should be targeted. A fibroid that causes pressure symptoms should have as much volume ablated as possible. Fibroids, which are located at the posterior wall, should have meticulous planning as structures such as the sacral bone and the adjacent lumbosacral nerves are in close proximity. Sciatic nerve injury can occur due to heat accumulation in the bone, which is transferred to the perineural fat and adjacent nerves.8

Fibroid with interposing bowel loops located along the potential beam path can be displaced by filling the urinary bladder with saline, filling the rectum with ultrasound gel, or using a convex gel pad. If the bowels cannot be shifted, the fibroid should be excluded from ablation as air bubbles or hard particles present in the bowel may reflect or absorb the ultrasonic energy and may cause bowel perforation.

2. Fibroid volume

A large fibroid volume may not be completely ablated in a single session and may require a second treatment. Improvement of pressure symptoms caused by large fibroids may take a longer time and repeated sessions to allow for sufficient shrinkage. Patients who have a total fibroid volume of more than 500 cm3, or a hyper-intense fibroid on T2 weighted imaging are suggested to be pre-treated with a GnRH analogs for 3 months in an effort to reduce the size and vascularity of the fibroid.10 GnRH analogs are known to decrease the vascularity of fibroids, as evidenced by a decrease in a microvascular density marker, CD34, in surgical specimens.11

3. Fibroid intensity

Fibroid intensity correlates with energy absorption and thus, the ability to achieve NPV. Assessment of uterine fibroids on T2-weighted images can predict the outcome of ablation. (Funaki et al. classified uterine fibroids into three types according to T2 signal intensity:

  • type 1, low signal intensity comparable to that of skeletal muscle
  • type 2, intermediate signal intensity, lower than that of the myometrium and higher than that of the skeletal muscle
  • type 3, high signal intensity, equal to or higher than that of the myometrium12

Uterine fibroids, which demonstrate low signal intensity on T2-weighted images (type 1) usually yield the best energy absorption. Intermediate signal intensity fibroids (type 2) might show moderate energy absorption. Hyper-intense fibroids (type 3), which represent vascularization, fluid-rich tissues, or degeneration are more resistant to heating and may show poor energy absorption, thus are not suitable for MRgFUS. A study showed that peripheral rim high density around uterine fibroid on T2-weighted images, which is commonly found at submucosal location lowers the efficacy of ablation.13 Thermal dissipation occurs due to the additional cooling or heat-sink effect resulting from the flows in the lymphatic vessels, dilated veins, and/or edema.14

4. Subcutaneous fat layer

A thick fat layer might result in beam aberration. The majority of the fibroid mass should be no more than 12 cm depth away from the skin line, as this is the upper limit of the scanner.15 The subcutaneous tissue layer has a lower specific heat capacity, insulating properties, and lower blood supply than those of other tissues in the abdominal wall.16

Studies done by Mikami et al., Kim et al., and a recent study by Keserci et al., suggested that the thick subcutaneous and visceral fat tissue attenuates the energy from exposure to sonification and causes accumulation of heat at the near field of the ultrasound beam path.17,18,19 The accumulation of heat increases the risk of fat burn and decreases the beam focus quality, limiting the degree of tissue ablation of uterine fibroids.

Patients with scar tissue have a higher risk of skin burns due to higher ultrasound absorption than the surrounding tissue. As scar tissue has reduced blood supply and reduced nerve sensation, the cooling rate is reduced, and the patient is less likely to feel heat over the scar during the treatment. Patients with longitudinal scars in the beam path, including those that cannot be seen on the MR images, were previously excluded, as scar tissue may absorb the ultrasound energy and cause pain or even a skin burn. However, several techniques have been used to avoid the scar without affecting the clinical efficacy of the treatment. By angling the transducer to increase the protected the scar could be avoided by the energy beam (Figure 5). Another technique is to fill the bladder to push the targetted area away from the scar (Figure 6).20 Beam-shaping feature can be also used to reduce intensity of the ultrasound field (Figure 7).21

Scar patches such as acoustic patches and water-resistant polyethylene foam scar have been introduced to reflect the ultrasound energy.22,23 No serious adverse effects or significant difference of volume reduction were reported.

5

Image showing the path of the sonication beam positioned to avoid scar, artifact (black arrow) from the painted scar marker, and no visible scaring through the tissues on T2-weighted MR imaging.20

6

Pre- and post-bladder filling showing fibroid has been pushed upwards, clear of the scar.20

7

Treatment planning of the beam-shaping feature in a 42-year-old woman with uterine fibroid and transverse scar.21

Advantages

  • Non-invasive without the trauma of surgery;
  • Outpatient procedure, no hospitalization;
  • Fast recovery, women generally return to normal activity within days;
  • Quality of life, most patients report a significant relief from symptoms during the weeks following treatment;
  • Safe, minimal side effects with no drugs;
  • Uterine-sparing, maintains natural hormonal function;
  • May be considered in patients who seek fertility sparing options.

Indications24

  • Definitive diagnosis of the uterine fibroid(s) or adenomyosis as the source of symptoms;
  • Lesion(s) clearly visible on non-contrast MRI;
  • Patient is able to fit into MRI unit;
  • Patient can tolerate the procedure under conscious sedation or no sedation; the treatment does not require general anesthesia;
  • Patient is able to communicate sensations to the physician during the procedure.

Exclusion criteria24

Besides location and size of the fibroid, the other exclusion criteria are derived from the ExAblate commercial treatment guidelines:

  • Hemoglobin <10 mg/dL;
  • Patient has hemolytic anemia;
  • Patient has unstable cardiac status including the following:
    • Unstable angina pectoris on medication;
    • Documented myocardial infarction within 6 months of protocol entry;
    • Congestive heart failure requiring medication (other than diuretic);
    • Currently taking anti-arrhythmic drugs;
    • Severe hypertension (diastolic BP >100 on medication);
    • Presence of cardiac pacemaker;
  • Patient has severe cerebrovascular disease (multiple CVA or CVA within 6 months);
  • Patient is on anti-coagulation therapy or has an underlying bleeding disorder;
  • Evidence of uterine pathology other than leiomyoma;
  • Patient has an active pelvic infection;
  • Patient has an undiagnosed pelvic mass outside the uterus;
  • Patient's weight >110 kg;
  •  Patient with extensive longitudinal abdominal scarring in an area of the abdomen directly anterior to the treatment area;
  •  Patient with standard contra-indications for MR imaging such as non-MRI compatible implanted metallic devices;
  •  Individuals who are not able or willing to tolerate the required prolonged stationary prone position during treatment (approximately 3 h).

Steps to perform MRgFUS25

  • Patient preparation:
    • The patient’s abdomen is shaved and cleaned to remove any hair and also checked for the presence of any moles or scars as these may result in skin burns.
    • A urinary catheter is inserted to control uterine movement during treatment.
    • Adequate analgesia including suppository 100 mg diclofenac sodium, i.v. paracetamol 1 g, i.v. midazalom and i.v. pethidine in titrated dose.
    • The patient is then positioned prone on the ExAblate treatment table with her abdomen over the water bath containing the ultrasound transducer.
    • The patient's legs may be wrapped with compression stockings to reduce the risk of deep vein thrombosis.
    • Patient’s blood pressure, heart rate, oxygenation, and comfort level are monitored throughout the treatment.
    • Communication is provided through a two-way intercom and an emergency button.
  • Calibration:
    • A three-plane localizer and T2-weighted imaging are performed. This provides the system with information, which include patient’s position, MRI scan plane, and transducer location to maximize the window available for the treatment of fibroids (Figure 8).

    8

    Calibration is done using a three-plane localizer and T2-weighted imaging providing information to correlate with patient's positioning. Reproduced with permission from InSightec.24

  • Draw:
    • The region of treatment (ROT) is drawn such that a margin of at least 1 cm is kept from the serosal surfaces to minimize the risk of ablating the serosa, which causes severe pain. The volume of the fibroid is calculated for ablation. A safety line is drawn at the lower energy density region, which includes intestines, pubic bone, and lumbosacral spine (Figure 9).
    • If the fibroid lies too close to the sacral area, then ultrasound gel (approx 250cc) can be inserted rectally to displace the fibroids away from the area. A safe distance of 4 cm is necessary. If bowel has migrated anteriorly to the fibroid, then saline can be infused into the bladder. This may need to be followed with insertion of rectal gel.

    9

    Drawing of the area of sonication under MRI guidance. Reproduced with permission from InSightec.24

  • Plan (Figure 10):
    • The system automatically creates a treatment plan, based on the ROT prescribed and protocol selected.
    • The ablation of each focal volume of a tissue is called a sonication.
    • It is important to avoid the bowel as it can cause perforation. Manipulation using urinary bladder and rectal is helpful to reposition the fibroid.
    • Refrain from other obstacles on the beam path, as IUD, surgical clips, and surgical scars.

    10

    Number of sonication planned by machine based on the size of the fibroid. Reproduced with permission from InSightec.24

  • Treat (Figure 11):
    • Actual delivery of the energy to each of the planned locations for ablation of the planned region.
    • This shows real-time delivery of energy to the fibroid and areas that are not receptive to treatment.
    • There is no limit to the percentage of fibroid volume that can be treated though generally a 60–70% of ablation is necessary for good outcomes.26 The operator then chooses the treatment plan depending on the size and type of fibroid being treated. For “white fibroids”, a nominal high-density plan should be selected, otherwise a medium-density plan would be suitable.
    • The length of the sonication can then be selected and may vary from 10 to 45 mm. Based on the treatment plan chosen, the FUS system automatically displays a series of sonication to cover the region of treatment. Each spot is cylindrically shaped, 25 to 45 mm in length and 5 mm in diameter for a nominal fibroid.
    • The sonication beam path is carefully checked to ensure that it does not pass through any structure that should be avoided – such as the small bowel that can fall in front of the uterus. Generally, treating and ablating an 8 cm fibroid takes approximately 3 h of sonication (that is excluding the patient preparation and planning), depending on energy absorption and location of the fibroid. Fibroids that are larger than 10 cm are less suitable for the treatment because of the long treatment time. However, two options are available: (1) Treating the fibroid over two sessions performed preferably with the fibroid volume being split into a superior and an inferior region for each of the treatment. This is to avoid the ultrasound beam in the second treatment from passing through already treated regions if an anterior-posterior division was made. (2) Or as mentioned previously, use pre-treatment with GnRH agonist prior to MRgFUS to shrink the fibroid and improve treatment outcomes.15
    • After the last sonication, post contrast T1 weight images were obtained to assess the NPV%.

    11

    Indication of ablated areas and on-going sonication.

  • Follow up:
    • Monitor as an inpatient for one day. The patient can return to normal activities the next day without event or
    • The patient should be reviewed by the interventional radiologist and gynecologist within 2 weeks. Patients for whom treatment could not be completed because of the large size or number of fibroids can have a repeat treatment anytime after 1 week.
    • The Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire (UFS-QOL) is uterine fibroid-specific and can be used to evaluate outcomes post-treatment within the clinical setting.27
    • Follow-up contrast-enhanced MRI is performed after 6 months to assess the fibroid size.

Complications

According to reported data from more than 10,000 commercial treatments with ExAblate (2004–2014), the device-related serious complications rate is approximately 0.3%.24 Table 4 below shows the complication and number of cases reported.

4

Device-related complications in magnetic resonance–guided focused ultrasound surgery.

Device-related serious complication

Number of cases reported

Second/third degree skin burns

0.13%

Bowel injury

 0.1%

Nerve injury

<0.1% 

Bladder wall injury

<0.1%

Additional reported treatment-related side effects include abdominal pain, lumbar pain, fever, significant bleeding, and vaginal discharge. The cases of bowel perforation were due to movement of patient during treatment and the sonication focused directly on the patient’s intestine. In some cases, particularly in submucosal fibroids, the necrotic material was expelled via the vagina after treatment over the subsequent menstrual cycles.28 Caution should be exercised when treating submucosal fibroids that detach into the endometrial cavity as the necrotic material may lead to septic shock. Skin burns occurred due to direct skin heating or heat accumulation in the fat or muscle that expended to the skin. This can be rectified by the techniques described previously.

Post-treatment outcome

Follow up NPV

To assess the respond on MRgFUS, follow up MRI measuring NPV is done at least 3 months post-treatment. Higher NPVs are associated with greater efficacy. However, in a systemic review of 19 studies, only 9 studies had an NPV over 50%. Nevertheless, symptom improvement was similar among the studies.29 The different response despite an average NPV may be due to the various types of fibroids and the variation of signal intensity on T2 weight images as mentioned previously. A type 1 fibroid has the best energy absorption and thus produces a larger reduction in fibroid volume.

Quality of life

A systematic review based on UFS-QOL showed that patients who underwent MRgFUS with larger NPV had improvement of severe symptoms and overall quality of life.29 Patients with intramural and submucosal fibroids experience improvement of symptoms such as menorrhagia, while patients with subserosal fibroids experience improvement of mass effect and abdominal volume.

Fertility

Promising post-MRgFUS results are described in patients with uterine fibroids who wish to conceive.30 However, the inclusion criteria need to be selective by a thorough analysis of the case, patient’s age, tumor location, and related symptoms. Rabinovici et al. described 51 gestations in UF patients treated with non-perfused volume (NPV) of an average of over 40% (range: 5.5–100%). Among them, 45% had a solitary fibroid, 37% had two to six fibroids, 14% had more than six fibroids, and 4% had complicated adenomyosis. There were 21 cases and 22 delivery times, and the natural delivery rate was 64%.31 Zou et al. reported average time to pregnancy was 5.6 ± 2.7 month post-ablation in 80 gestations treated with ultrasound-guided HIFU.32 MRgFUS is safe and does not increase the rate of spontaneous abortions or pregnancy complications.33 Some authors found that vaginal delivery is preferable post-MRgFUS as there is no surgery involved, no adhesion found and thus no risk of uterine wall rupture during gestation and delivery.33,34

PRACTICE RECOMMENDATIONS

  • Patient selection for this therapeutic modality is based on symptoms, site and size of pathology, number of lesions and intensity on imaging.
  • Patient planning on the day of the procedure is also essential due to mobile characteristic of the uterus and its close proximity to the surrounding structures.


CONFLICTS OF INTEREST

The author(s) of this chapter declare that they have no interests that conflict with the contents of the chapter.

REFERENCES

1

Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188(1):100–7.

2

Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women’s Health 2012;12(1):1–11.

3

Ferenczy AJ. Pathophysiology of adenomyosis. Hum Reprod Update 1998;4(4):312–22.

4

Park H, Yoon S-W, Kim K-A, et al. Magnetic resonance imaging–guided focused ultrasound treatment of pedunculated subserosal uterine fibroids: a preliminary report. J Vasc Interv Radiol 2012;23(12):1589–93.

5

Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206(3):211. e1–.e9.

6

De La Cruz MSD, Buchanan EM. Uterine fibroids: diagnosis and treatment. Am Fam Physician 2017;95(2):100–7.

7

Chen J, Li Y, Wang Z, et al. Evaluation of high‐intensity focused ultrasound ablation for uterine fibroids: an IDEAL prospective exploration study. BJOG 2018;125(3):354–64.

8

Duc NM, Keserci B. Emerging clinical applications of high-intensity focused ultrasound. Diagn Interv Radiol 2019;25(5):398.

9

Fan H-J, Cun J-P, Zhao W, et al. Factors affecting effects of ultrasound guided high intensity focused ultrasound for single uterine fibroids: a retrospective analysis. Int J Hyperthermia 2018;35(1):534–40.

10

Lethaby A, Vollenhoven B, Sowter M. Pre‐operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001(2).

11

Di Lieto A, De Falco M, Staibano S, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003;22(4):353–8.

12

Funaki K, Fukunishi H, Funaki T, et al. Magnetic resonance-guided focused ultrasound surgery for uterine fibroids: relationship between the therapeutic effects and signal intensity of preexisting T2-weighted magnetic resonance images. Am J Obstet Gynecol 2007;196(2):184. e1–.e6.

13

Yeo SY, Kim Y-S, Lim HK, et al. Uterine fibroids: Influence of “T2-Rim sign” on immediate therapeutic responses to magnetic resonance imaging-guided high-intensity focused ultrasound ablation. Eur J Radiol 2017;97:21–30.

14

Mittl Jr R, Yeh I-T, Kressel H. High-signal-intensity rim surrounding uterine leiomyomas on MR images: pathologic correlation. Radiology 1991;180(1):81–3.

15

Chen R, Keserci B, Bi H, et al. The safety and effectiveness of volumetric magnetic resonance-guided high-intensity focused ultrasound treatment of symptomatic uterine fibroids: early clinical experience in China. J Ther Ultrasound 2016;4(1):1–9.

16

Henriques Jr F, Moritz AR. Studies of thermal injury: I. The conduction of heat to and through skin and the temperatures attained therein. A theoretical and an experimental investigation. Am J Pathol 1947;23(4):530.

17

Kim Y-S, Lim HK, Kim J-H, et al. Dynamic contrast-enhanced magnetic resonance imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest Radiol 2011;46(10):639–47.

18

Mikami K, Murakami T, Okada A, et al. Magnetic resonance imaging-guided focused ultrasound ablation of uterine fibroids: early clinical experience. Radiat Med 2008;26(4):198–205.

19

Keserci B, Duc NM. Magnetic resonance imaging parameters in predicting the treatment outcome of high-intensity focused ultrasound ablation of uterine fibroids with an immediate nonperfused volume ratio of at least 90%. Acad Radiol 2018;25(10):1257–69.

20

Zaher S, Gedroyc W, Lyons D, et al. A novel method to aid in the visualisation and treatment of uterine fibroids with MRgFUS in patients with abdominal scars. Eur J Radiol 2010;76(2):269–73.

21

Kim Y-S, Bae D-S, Park MJ, et al. Techniques to expand patient selection for MRI-guided high-intensity focused ultrasound ablation of uterine fibroids. AJR Am J Roentgenol 2014;202(2):443–51.

22

Yoon S-W, Seong SJ, Jung S-G, et al. Mitigation of abdominal scars during MR-guided focused ultrasound treatment of uterine leiomyomas with the use of an energy-blocking scar patch. J Vasc Interv Radiol 2011;22(12):1747–50.

23

Keserci B, Duc NM. Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects. J Ther Ultrasound 2017;5(1):1–10.

24

(InSightec) I-IGTL. MR guided Focused Ultrasound Surgery. Information for Prescribers For Uterine Fibroid and Adenomyosis Treatments August 2010.

25

Abdullah B, Subramaniam R, Omar S, et al. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) treatment for uterine fibroids. Biomed Imaging Interv J 2010;6(2):e15.

26

Stewart EA, Rabinovici J, Tempany CM, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006;85(1):22–9.

27

Spies JB, Bradley LD, Guido R, et al. Outcomes from leiomyoma therapies: comparison with normal controls. Obstet Gynecol 2010;116(3):641–52.

28

Wang W, Wang Y, Wang T, et al. Safety and efficacy of US-guided high-intensity focused ultrasound for treatment of submucosal fibroids. Eur Radiol 2012;22(11):2553–8.

29

Peregrino PFM, de Lorenzo Messina M, dos Santos Simões R, et al. Review of magnetic resonance-guided focused ultrasound in the treatment of uterine fibroids. Clinics (Sao Paulo) 2017;72:637–41.

30

Ciebiera M, Łoziński T. The role of magnetic resonance-guided focused ultrasound in fertility-sparing treatment of uterine fibroids – current perspectives. Ecancermedicalscience 2020;14.

31

Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010;93(1):199–209.

32

Zou M, Chen L, Wu C, et al. Pregnancy outcomes in patients with uterine fibroids treated with ultrasound‐guided high‐intensity focused ultrasound. BJOG 2017;124:30–5.

33

Łoziński T, Filipowska J, Gurynowicz G, et al. The effect of high-intensity focused ultrasound guided by magnetic resonance therapy on obstetrical outcomes in patients with uterine fibroids–experiences from the main Polish center and a review of current data. Int J Hyperthermia 2019;36(1):581–9.

34

Liu X, Xue L, Wang Y, et al. Vaginal delivery outcomes of pregnancies following ultrasound-guided high-intensity focused ultrasound ablation treatment for uterine fibroids. Int J Hyperthermia 2018;35(1):510–7.

Online Study Assessment Option
All readers who are qualified doctors or allied medical professionals can now automatically receive 2 Continuing Professional Development credits from FIGO plus a Study Completion Certificate from GLOWM for successfully answering 4 multiple choice questions (randomly selected) based on the study of this chapter.
Medical students can receive the Study Completion Certificate only.

 

(To find out more about FIGO’s Continuing Professional Development awards programme CLICK HERE)